Author: admin

  • Skipping breakfast and eating late dinners might be silently damaging your bones. New study reveals shocking risk

    Skipping breakfast and eating late dinners might be silently damaging your bones. New study reveals shocking risk

    We’ve all heard that breakfast is the most important meal of the day. But a new study suggests it’s more than just energy and mood—it could be about your bones. Researchers from Nara Medical University in Japan found that skipping breakfast and eating dinner late are independently linked to osteoporosis, a disease that quietly weakens bones until fractures strike. This revelation is adding urgency to the call for healthier meal routines.

    How Late Eating Habits Put Bones at Risk

    The research, recently published in the Journal of the Endocrine Society and reported by Fox News Digital, tracked the lifestyle habits of over 927,000 adults. Participants, aged 20 and older, were followed for nearly three years to monitor who developed fractures in the hip, spine, wrist, or upper arm—common indicators of osteoporosis.
    The findings were clear. People who skipped breakfast more than three times a week or ate dinner within two hours of going to bed on a regular basis were at a significantly higher risk of bone fractures. These behaviors were also associated with other unhealthy habits like smoking, drinking alcohol daily, and inadequate sleep and exercise.
    Lead author Dr. Hiroki Nakajima told Fox News Digital, “We demonstrated that these eating patterns frequently co-occurred with other unhealthy behaviors—suggesting that comprehensive lifestyle counseling may be important for fracture prevention.”

    Even after adjusting for other risk factors, such as age and body mass index, the link between irregular eating patterns and bone health remained. “Not having a routine eating schedule was independently associated with a higher risk of osteoporotic fractures,” the study noted.

    iStock

    Osteoporosis is a progressive bone disease where bones become weak, brittle, and fragile, increasing the risk of fractures. It often develops silently. (Image: iStock)

    The Science Behind the Clock and Bones

    The Japanese findings echo conclusions from a broader body of research, including insights from a 2019 review published in Nutrients, which highlights the critical role of meal timing in regulating our internal clocks. The body’s circadian rhythms, controlled by light exposure and biological clocks in the gut, liver, and muscles, help regulate everything from glucose absorption to hormone secretion. The review explained that eating late at night disrupts these rhythms, impairing metabolic processes and reducing the body’s ability to absorb nutrients crucial for bone strength. “Food consumption that is asynchronous with natural circadian rhythms may exert adverse health effects and increase disease risk,” the authors wrote. Moreover, skipping breakfast may lead to increased post-meal insulin spikes and fat oxidation imbalance, contributing not just to poor glucose control but also to inflammation—a silent trigger in bone degradation.

    Building Healthy Routines

    Experts say meal timing isn’t about strict diets or impossible schedules—it’s about consistency. Registered dietitian Su-Nui Escobar, not involved in the study but quoted in Fox News Digital, emphasized the importance of simple, sustainable routines. “Establishing routines—like having meals at specific times—supports our well-being without requiring constant thought or reliance on willpower,” she said.
    She recommends easy-to-prepare breakfasts such as Greek yogurt with fruit, overnight oats, or egg muffins, and dinners like pan-fried salmon with vegetables—all options that keep meal timing intact without stressing busy schedules.

    What This Means for You

    Osteoporosis is often called a “silent disease” because many people don’t know they have it until a fracture occurs. According to the National Institutes of Health, it’s a leading cause of fractures in post-menopausal women and older men, with bone loss progressing quietly over time.

    The takeaway? Eating habits aren’t just about calorie counts—they can influence long-term bone health. Prioritizing regular meal times, eating breakfast, and avoiding late dinners may seem small, but they could be key steps toward reducing your risk of fractures and metabolic diseases.

    As the Nutrients review concluded, “A regular meal pattern including breakfast consumption, consuming a higher proportion of energy early in the day, reduced meal frequency, and regular fasting periods may provide physiological benefits such as reduced inflammation, improved circadian rhythmicity, and stress resistance.”

    Add ET Logo as a Reliable and Trusted News Source

    Continue Reading

  • Experimental brain stimulation may help turn off the ‘fire alarm’ of chronic pain – KION546

    Experimental brain stimulation may help turn off the ‘fire alarm’ of chronic pain – KION546

    By Jen Christensen, CNN

    (CNN) — Edward Mowery lived with excruciating pain for years: Picture being put into a hot frying pan, he said, and then someone holding you down on that pan forever. The fiery, shooting pain got so bad that he quit his job, stopped playing sports and had to abandon his beloved death metal band just as the group was taking off.

    “At one point, I didn’t have any feeling in my arms or hands or anything,” said Mowery, 55, who lives in New Mexico. “I couldn’t put one note on a guitar, much less play like I do.”

    But everything changed when doctors tried a cutting-edge approach to pain management. If they can refine the technique to make it less intrusive and demonstrate that it works on others, doctors think this technique could radically transform the way people manage debilitating and otherwise untreatable chronic pain — no opioids or pain blockers required.

    “The state of the art right now for picking a medication for an individual patient is trial and error” when it comes to pain, said Dr. Prasad Shirvalkar, a neurologist at the University of California San Francisco. “Trying to be your own guinea pig, that’s essentially what we’re doing right now in pain medicine.” Finding something more precise that could stop a pain signal in the brain before it could be felt in the body would be a huge shift.

    An estimated 50 million adults in the United States experience chronic pain, defined as lasting for more than three months. Of them, about 8.5% are like Mowery, living with chronic pain that interferes with day-to-day life, according to the US Centers for Disease Control and Prevention.

    Years of agony

    Mowery says he was a rambunctious kid and got injured a lot while skiing and playing soccer.

    Altogether he says he’s had 34 surgeries, including 11 painful knee surgeries, as well as foot, back and neck surgeries. The bigger problem, though, started with a part of his body that hadn’t even been injured.

    About a week after a routine knee replacement in 2009, his right foot started to feel like it was on fire.

    He spoke with “all kind of doctors, trying to figure out what was going on,” but nobody could explain the pain. Some didn’t even believe that he was in pain, assuming he was an opioid addict looking for pills. “That’s the one thing, when they put me on all these meds, I wasn’t addicted to all the meds, I was addicted to getting rid of the pain,” he said.

    For eight long years, he said, doctors couldn’t figure out what was causing the pain. But in 2017, when his foot turned purple and black, he went to a pain specialist in Albuquerque who took one look and told him he had complex regional pain syndrome, or CRPS.

    CRPS is a kind of neurological pain, often in the extremities, that can develop after a surgery, stroke, injury or heart attack that is out of proportion to the severity of an initial injury. It can make blood vessels dilate or constrict, leading to skin discoloration, swelling and temperature changes.

    Mowery says doctors explained that when the acute pain from his knee went away, his brain essentially missed that feeling.

    “Because I’d been in pain for so long, my brain was so used to being in pain that it said, ‘Oh, you need to have this back,’ ” he said. “Manufactured pain from the brain with no stimulus. It’s unreal.”

    Doctors put him on a variety of pain medications, including morphine and oxycodone, that he didn’t like because he felt so out of it. At one point, he took 17 pills a day, but nothing worked for long. Always athletic, Mowery ended up relying on a walker or a wheelchair to get around.

    “It’s really depressing. You would think they’d call CRPS the suicide disease,” Mowery said. “A lot of times, I was sitting there just going, ‘what am I going to do? There’s nothing out there for me.’ “

    He spent years searching the internet for clinical trials and finally found one at the University of California San Francisco. The description of the research seemed vague but he filled out the questionnaire anyway and, within 40 minutes, he said, he got a message urgently asking him to come to San Francisco.

    Relief from his years of agony would soon come after doctors persuaded him to let them drill several holes in his head.

    ‘These are people that have been failed’

    Shirvalkar says he has long wanted to solve the puzzle that is pain. He had success treating neurological conditions but less success treating their chronic pain.

    “There are people that have been failed by all available therapies. They’ve tried over 25 different medications. They have had multiple injections and nerve blocks.
    They’ve even had spinal cord stimulators or peripheral stimulators, and nothing can alleviate their suffering,” Shirvalkar said. “We started appreciating that the brain must be generating or perpetuating these pain signals in a person. So the question becomes, how can we identify what these signals are and really try to suppress or short-circuit them?”

    Acute pain, like when someone stubs a toe, affects the brain differently from chronic pain, he said.

    “I think of chronic pain as a fire alarm. The alarm is helpful for acute pain. We want to be able to know when there’s an emergency,” he said. “In chronic pain, it’s as if the fire alarm is going off, but we can’t identify the fire.”

    When pain becomes chronic, it rewires the brain.

    “It starts to take on these other dimensions that include mood and motivation and involve attention and memory, and so we really have to address the cognitive aspect of it,” Shirvalkar said. “It tells me that when someone has developed chronic pain, treating it with a single drug or injection or some monotherapy probably isn’t going to work.”

    With the help of a $7.56 million grant from the National Institutes of Health, Shirvalkar and a team at UCSF have been exploring deep brain stimulation, a technology sometimes used with people who have Parkinson’s disease, to treat pain conditions like Mowery’s.

    With Parkinson’s, doctors implant electrodes in the brain that produce electrical impulses to disrupt the abnormal signals that cause tremors, stiffness and slow movement. Shirvalkar wondered if they could also use the a version of the device to redirect or suppress the brain’s pain signals to the body.

    There were a few challenges with this approach. The device sends signals around the clock in someone who has Parkinson’s, but Shirvalkar thought a constant signal wouldn’t work for chronic pain because the brain can become acclimated to the impulses and essentially override them.

    Another challenge was figuring out what part of the brain was sending pain signals.
    There’s no one central location that does this, and it could be different in different people.

    Yet another challenge would be to quickly sense when the brain was about to send out a pain signal – or even anticipate it – and shut it down quickly.

    The team used computational models and AI to essentially detect a biomarker that could track how severe a person’s chronic pain would be, similar to how an A1C level can tell whether someone has diabetes and how severe it is.

    But to learn whether deep brain stimulation could work for pain, the team first had to persuade Mowery that he should have another surgery. He was reluctant to have another procedure. This trial would require three.

    ‘I feel like I owe him my life’

    It took Mowery about 18 months to decide the trial was right for him – time in which the worsening pain essentially wore him down.

    In the first surgery, doctors would map Mowery’s brain to determine where the pain came from. Another surgery would remove the temporary probes from the first procedure. A final procedure placed permanent probes in the correct areas.

    For the first part of the trial, Mowery spent 10 days in the hospital while doctors created a grid of more than 100 points on his head to try to find different circuits or certain activation for pain by watching and stimulating his brain. Even with eight- to 10-hour days probing his brain, it wasn’t until day five or six that the researchers had their “eureka moment.”

    “All of a sudden, Ed says, ‘Wow, my pain just washed off of me,’ ” Shirvalkar said. “I was blown away. I didn’t know what to say.”

    Concerned that it could be the placebo effect, the doctors kept testing to make sure they had the right targets. Shirvalkar quickly became confident that they had picked the right areas when Mowery immediately felt the pain in his feet, legs and lower back dissipate.

    “When it comes to actually understanding what’s driving someone’s chronic pain, we say there’s no pain center, right? But it tells us if chronic pain is this complex lock, it tells us that yes, that there is a key to be found. So it gives us hope.”

    Much more research will be done to see if this technology can work for everyone or whether there would be even better technology that would be less invasive.

    In August, Shirvalkar and his team published the results of their tests of this technique on six people. The team followed the patients for 22 months and were even able to randomize the trial so some got the stimulation and some did not. Those who got stimulation reported a reduction in pain of about 60%, while the placebo group got no such relief.

    Mowery has resumed his normal daily activities, including playing his guitar. He can monitor what’s going on in his brain with an iPad app and just has to periodically charge the device that sends the signals to his brain.

    He’s not totally pain-free, he says: He’ll have a bad day sometimes, but it’s infrequent.

    He says Shirvalkar’s work changed his life.

    “The way it detected pain, the way it turns off pain, the way I’m getting off all these medications, I feel like I owe him my life,” Mowery said.

    Mowery felt so much better that, in June, he accompanied Shirvalkar to Washington to testify before Congress’ Neuroscience Caucus about the impact of the NIH BRAIN Initiative on addiction research and on this pain treatment alternative.

    Shirvalkar is concerned about future funding amid the current political environment and other funding cuts at the NIH.

    “NIH funding is always a concern. Fortunately, we’re doing OK for the time being,” Shirvalkar said. “We’ll have to wait and see.”

    Mowery hopes that his experience will provide enough of an example so people can see the possibilities of such medical research.

    “I have been called a medical astronaut before, and my sister is an actual astronaut, and she finds that funny,” Mowery said. “It’s a miracle.”

    The-CNN-Wire
    ™ & © 2025 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

    Continue Reading

  • Lewis Capaldi review – an emotional return to the spotlight for pop’s most heart-on-sleeve star | Lewis Capaldi

    Lewis Capaldi review – an emotional return to the spotlight for pop’s most heart-on-sleeve star | Lewis Capaldi

    Lewis Capaldi is a pop star known for his patter. But tonight, he warns the crowd he is feeling too overwhelmed to perform his usual funnyman routine. “I probably won’t say lots this evening because I don’t know what to say,” he says. “I’m just genuinely thrilled that this is still a possibility for me.”

    The 28-year-old being lost for words tonight is understandable. In 2023, Capaldi announced he was taking a hiatus from touring, after sharing his struggles with his mental health and his diagnosis in 2022 of Tourette syndrome. Having disappeared from the spotlight for the better part of two years, he made a triumphant return at Glastonbury earlier this summer for an unannounced and emotional set on the Pyramid stage. Tonight’s Sheffield show, however, marks the Scottish singer’s first headline performance since his extended break. “We’re back baby,” he tells the crowd at one point.

    The show begins with Survive, with Capaldi singing “I still got something to give / Though it hurts sometimes / I’m gonna get up and live” over thunderous drums and lashings of guitar. As he hurtles through Grace and Heavenly Kind of State of Mind, he seems incredulous, nervously giggling as he gazes out at the audience. But by the time he performs Forever – complete with mass audience singalong – he has relaxed into it and shaken off any disbelief at being back.

    Lewis Capaldi Performs At Utilita Arena Photograph: Shirlaine Forrest/Getty Images

    Capaldi’s music has never been especially adventurous: it’s his voice – raspy and emotive – that’s the appeal. But absent his usual onstage banter, the back-to-back balladry and heartbreak anthems do begin to merge. The homogeny is thankfully broken up by the schmaltzy 80s stylings of Leave Me Slowly, with its pillowy electric pianos and guitar solo, and the poppier melodies of Forget Me also offer a little variation.

    The most striking moment comes during The Day That I Die, a new song Capaldi says was written “at a time I didn’t know I would be around”. Sat at the piano following a raging final chorus, his voice stormy with emotion, Capaldi lowers his head and cries. It’s a performance that clearly takes a toll. However, judging by his face during the encore of Someone You Loved, the price was worth paying. “It means everything that we’re back doing this,” he says with a grin. “Excuse the pun, but I’ll be doing it till the day I die.”

    At Utilita Arena, Sheffield, 7 September, and touring the UK until 27 September

    Continue Reading

  • Figure skating – ISU CS Kinoshita Group Cup 2025: Hiccups and all, Cha Junhwan still cruises to men’s title

    Figure skating – ISU CS Kinoshita Group Cup 2025: Hiccups and all, Cha Junhwan still cruises to men’s title

    Cha Junhwan became the inaugural men’s Kinoshita Group Cup 2025 champion on Sunday (7 September) in Osaka although he was left shaking his head after what turned out to be a comfortable win over his peers.

    As the Republic of Korea’s two-time Olympian did in the short program, Cha topped the free skating by more than 10 points over runner-up Tomono Kazuki for a score of 165.55 and a total of 253.31.

    Tomono was a distant second with 236.78 as Cha lifted his first trophy of the Milano Cortina 2026 season.

    But the 23-year-old Cha was not particularly pleased with his performance on the night when he popped his opening jump – a quad Salchow-triple toeloop combo – and faltered on a couple of other combinations.

    “I was a bit disappointed about that,” said Cha, who has chosen “Moulin Rouge” for his free skate music.

    “I popped the first jump and at practice it was very consistent but I made a mistake. I had to really focus so I was a little bit disappointed with myself. It could happen in the future too so I will work on that.”

    Still Cha, who has been assigned to the Cup of China and will be back in Japan in November for the NHK Trophy, thinks there were plenty of takeaways from Sunday’s outing that he can build on for the rest of the campaign.

    He said: “It’s really early in the season. So from today I can get a lot of feedbacks and I can work on so many things.

    “I made mistakes and can make the quality of the jumps better, and the footwork. I think two days ago in an interview I said I was like 60, 70 per cent ready but today I was like 40, 50 per cent.

    “So I will keep pushing through and then it will get better and better and it will be improved more by the end of the season.”

    Continue Reading

  • See How Much Prices Surged

    See How Much Prices Surged

    President Donald Trump’s tariffs are now hitting gamers hard, with console prices jumping across the board. Sony is the latest brand to announce price increases to its PlayStation consoles, following in the footsteps of Microsoft’s Xbox and Nintendo’s Switch.

    Learn More: I Asked ChatGPT What the Point of Trump’s Tariffs Are: Here’s What It Said

    Read Next: 7 Tax Loopholes the Rich Use To Pay Less and Build More Wealth

    Here’s how much tariffs have added to the price of PlayStations and other popular consoles.

    Sony announced that it would be raising the prices on its PlayStation devices effective Aug. 21.

    “Similar to many global businesses, we continue to navigate a challenging economic environment,” the company stated in a blog post. “As a result, we’ve made the difficult decision to increase the recommended retail price for PlayStation 5 consoles in the U.S.”

    According to Forbes reporting, the new prices reflect a $50 increase:

    • PlayStation 5: Formerly $499.99, now costs $549.99

    • PlayStation 5 Digital Edition: Formerly $449.99, now costs $499.99

    • PlayStation 5 Pro: Formerly $699.99, now costs $749.99

    Find Out: Mark Cuban: Trump’s Tariffs Will Affect This Class of People the Most

    Prior to Sony’s announcement, Microsoft announced that it would be increasing the costs of its Xbox games and devices in May.

    “We understand that these changes are challenging, and they were made with careful consideration given market conditions and the rising cost of development,” the company stated on its site.

    In addition to bumping the price of some Xbox games to $79.99 — up from the standard of $70 — Microsoft also increased the costs of some of its consoles by more than 20%:

    • Xbox Series S with 512 GB of storage: Formerly $299.99, now costs $379.99 (26% increase)

    • Xbox Series S with 1 TB of storage: Formerly $349.99, now costs $429.99 (22% increase)

    • Xbox Series X 2TB Galaxy Special Edition: Formerly $599.99, now costs $729.99 (21% increase)

    • Xbox Series X Digital: Formerly $449.99, now costs $549.99 ($100 increase)

    • Xbox Series X: Formerly $499.99, now costs $599.99 ($100 increase)

    In April, Nintendo announced that it would be releasing the Nintendo Switch 2 with a suggested retail price of $449.99. That marks a 50% increase from the price of the original Switch, which was released in 2017. The company also hiked the prices of Switch 2 accessories by $5 to $10 each that month, Forbes reported.

    More From GOBankingRates

    This article originally appeared on GOBankingRates.com: Trump’s Tariffs Hit PlayStation, Xbox and Switch: See How Much Prices Surged

    Continue Reading

  • Armstrong edges closer to maiden win at ERC Ceredigion

    Armstrong edges closer to maiden win at ERC Ceredigion

    The M-Sport Ford World Rally Team driver extended his lead to 13.8sec over team-mate Romet Jürgenson, while ERC championship pacesetter Miko Marczyk held onto third, 31.2sec down on the flying Armstrong. M-Sport and Ford remain on course for their first ERC wins since Adrien Fourmaux’s triumph on Rally Islas Canarias in November 2020.

    Marczyk’s nearest title rival Andrea Mabellini continues his fightback from a two-minute penalty issued before the event to sit in sixth overall, albeit 2min 44.7sec adrift of first place.

    Overcast skies and the threat of rain threw an extra curveball for crews when it came to selecting tyres. Rally leader Armstrong trusted his weather crew and opted against taking any wet tyres as part of his package.

    The Motorsport Ireland Rally Academy driver’s call was reflected in the times to win SS9, Nant y Moch, that was held in dry conditions. It was Armstrong’s third stage win of the event, which he captured ahead of fellow Pirelli-shod team-mate Jürgenson by 3.3sec to grow his lead over the Estonian to 10.6sec.

    The heavy rain stayed away for SS10, Mynnydd Bach, where Armstrong notched up his fourth stage best, posting a time 2.7sec faster than Marczyk, that was crucially 3.2sec quicker than Jürgenson.

    “I would say we were quite lucky [to avoid the heavy rain] as it was starting to rain a bit towards the end, but nothing heavy. But it makes you think there could be a slippy corner coming up. It was quite a safe run, so to be faster is great,” said Armstrong.

    Jürgenson remains on course for an ERC podium

    © ERC

    Jürgenson made a small error at the hairpin in the stage as he dropped further behind Armstrong.

    “To be honest it didn’t feel so good. Getting into the stage I didn’t have the feeling to push and a real reason to do it. I know today, Jon is probably a bit faster than me so I don’t want to risk everything and with the soft tyres the understeer was quite crazy, I messed up the handbrake place too so not the best stage,” said the FIA Rally Star driver.

    Probite British Rally Championship leader William Creighton, who was among the majority of crews to carry two spare wet tyres for the loop, managed to take 3.2sec out of Miko Marczyk on SS9 to close the gap in the fight for third to 6.9sec.

    The Michelin-shod Marczyk responded to Creighton’s effort by taking 1.5sec out of the Irishman on SS10. Creighton did however carry a transmission issue that prevented him from putting his Toyota GR Yaris Rally2 car in neutral.

    Marczyk still holds the ERC title initiative

    Marczyk still holds the ERC title initiative

    © ERC

    Callum Devine and Max McRae, both running on MRF Tyres, rejoined the rally following their retirements from yesterday’s action. Devine’s return only lasted one stage as a second engine fire brought the Irishman to a halt in SS10. Meanwhile, McRae was also lucky to survive a wild slide during the stage.

    Two-time Rali Ceredigion winner Osian Pryce’s decision to go for a wet set-up backfired, but the Welshman was able to maintain fifth overall, 57.2sec ahead of ERC title contender Mabellini, with Callum Black in seventh, 3m22.7sec down on top spot.

    ERC3 leader Eamonn Kelly held eighth in front of local hero and ERC4 pacesetter Ioan Lloyd, while Meirion Evans rounded out the top 10.

    Crews will complete a second pass of the stages this afternoon to conclude the 2025 JDS Machinery Rali Ceredigion with the event-deciding Power Stage due to begin at 15h05 local time.

    Continue Reading

  • New Diet Slows Growth of Deadliest Brain Tumors in Mice

    New Diet Slows Growth of Deadliest Brain Tumors in Mice

    Scientists have uncovered how deadly brain tumors hijack the body’s energy sources, and found that tweaking diet may help slow their growth. Credit: Shutterstock

    Researchers have discovered that brain cancer cells reprogram their sugar metabolism, a vulnerability that can be exploited in mice to impede tumor growth and enhance therapeutic outcomes.

    Glioblastomas are the most aggressive type of malignant brain tumor, and patients diagnosed with this condition typically survive only one to two years.

    Within these tumors, ordinary brain cells change their behavior, multiplying quickly and spreading into nearby tissue. Unlike healthy brain cells, the cancerous cells process nutrients in a fundamentally different way.

    In a recent study published in Nature, scientists at the University of Michigan, including experts from the Rogel Cancer Center, the Department of Neurosurgery, and the Department of Biomedical Engineering, investigated how glioblastoma cells metabolize glucose.

    Their findings revealed that these tumors rely on distinct nutrient pathways compared to normal brain tissue, offering new insight into potential treatment strategies.

    “We altered the diet in mouse models and were able significantly slow down and block the growth of these tumors,” said co-senior author Daniel Wahl, M.D., Ph.D., associate professor of radiation oncology.

    “Our study may help create new treatment opportunities for patients in the near future.”

    Conventional treatments consist of surgery followed by radiation therapy and chemotherapy. However, the tumors eventually return and become resistant to treatment.

    Previously, researchers have shown that resistance is due to metabolic rewiring within cancer cells.

    Cancer cells in the brain use sugars differently compared to healthy cells

    Metabolism is the process by which our bodies break down molecules like carbohydrates and proteins so that our cells can either use them or build new molecules.

    Although both brain and cancer cells depend on sugar, the team wanted to see if they use sugar differently.

    They injected small amounts of labelled sugar into mice and, importantly, into patients with brain tumors to follow how it is used.

    “To really understand these brain cancers and improve treatments for patients, we needed to do the hard work of studying the tumors in patients themselves, not just in the lab,” said co-senior author Wajd Al-Holou, M.D., a brain tumor neurosurgeon who co-directs the Michigan Multidisciplinary Brain Tumor Clinic.

    Although both normal tissues and tumor cells used a lot of sugar, they used it for different purposes.

    Brain Cells Sugar Glioblastomas Graphic
    Brain cells use sugar (white) to make chemicals (green) that allow the brain to function properly. Glioblastomas, on the other hand, converted sugar into molecules (red) that help them invade the surrounding tissues. Credit: Justine Ross, Michigan Medicine

    “It’s a metabolic fork in the road,” said Andrew Scott, Ph.D., a research scholar in Wahl’s lab.

    “The brain channels sugar into energy production and neurotransmitters for thinking and health, but tumors redirect sugar to make materials for more cancer cells.”

    The team found that healthy tissues used sugars to generate energy and make chemicals that allow the brain to function properly.

    Glioblastomas, on the other hand, turned off those processes and instead converted sugar into molecules like nucleotides—the building blocks of DNA and RNA—that helped them grow and invade the surrounding tissues.

    Amino-acid restricted diets can improve treatment outcomes in mice

    The researchers also noticed other important differences.

    The normal brain used sugar to make amino acids, the building blocks of proteins. However, brain cancers seemed to turn this pathway off and instead scavenged these amino acids from the blood.

    This finding led the researchers to consider whether lowering the levels of certain amino acids in the blood could affect brain cancer without affecting the normal brain.

    They tested whether mice that were fed an amino acid-restricted diet had better treatment outcomes.

    “When we got rid of the amino acids serine and glycine in the mice, their response to radiation and chemotherapy was better and the tumors were smaller than the control mice that were fed serine,” said co-senior author Deepak Nagrath, Ph.D. professor of biomedical engineering.

    Based on their measurements in mice, the team also built mathematical models that can track how glucose is being used in different pathways, which can help identify other drug targets.

    Co-senior author Costas Lyssiotis, Ph.D., professor of molecular and integrative physiology, compared metabolic pathways to roads and drugs to roadblocks.

    Dropping a roadblock on a fast highway with a lot of traffic will have a greater effect than blocking a country road with a lower speed limit and only a few cars.

    Similarly, in a normal brain, the uptake of the amino acid serine from the blood is like a slow country road.

    But brain cancer is like a busy freeway, giving researchers the opportunity to selectively target the cancer.

    The team is working on opening clinical trials soon to test whether specialized diets that limit blood serine levels can also help glioblastoma patients.

    “This is a multidisciplinary effort from across the university,” Wahl said.

    “It is a study that no individual investigator could do on their own and I’m grateful to be part of a team that works together to make important discoveries that can improve treatments for our patients.”

    Reference: “Rewiring of cortical glucose metabolism fuels human brain cancer growth” by Andrew J. Scott, Anjali Mittal, Baharan Meghdadi, Alexandra O’Brien, Justine Bailleul, Palavalasa Sravya, Abhinav Achreja, Weihua Zhou, Jie Xu, Angelica Lin, Kari Wilder-Romans, Ningning Liang, Ayesha U. Kothari, Navyateja Korimerla, Donna M. Edwards, Zhe Wu, Jiane Feng, Sophia Su, Li Zhang, Peter Sajjakulnukit, Anthony C. Andren, Junyoung O. Park, Johanna ten Hoeve, Vijay Tarnal, Kimberly A. Redic, Nathan R. Qi, Joshua L. Fischer, Ethan Yang, Michael S. Regan, Sylwia A. Stopka, Gerard Baquer, Krithika Suresh, Jann N. Sarkaria, Theodore S. Lawrence, Sriram Venneti, Nathalie Y. R. Agar, Erina Vlashi, Costas A. Lyssiotis, Wajd N. Al-Holou, Deepak Nagrath and Daniel R. Wahl, 3 September 2025, Nature.
    DOI: 10.1038/s41586-025-09460-7

    Funding/disclosures: Scott was supported by the National Cancer Institute (K99CA300923; F32CA260735). Wahl was supported by NCI (K08CA234416; R37CA258346), National Institute of Neurological Disorders and Stroke (R01NS129123), Damon Runyon Cancer Foundation, Sontag Foundation, Ivy Glioblastoma Foundation, Forbes Institute for Cancer Discovery, Alex’s Lemonade Stand Foundation and Chad Tough Defeat DIPG foundation. Wahl and Lawrence were supported by NCI P50CA269022. Nagrath was supported by NCI (R01CA271369). Wu, Feng and Qi were supported by NIDDK MMPC-Live (1U2CDK135066). Zhou was supported by University of Michigan Medical School’s Pandemic Research Recovery grant (U083054). Al-Holou was supported by NINDS (K08NS12827101), American Cancer Society (CSDG-23-1031584-01-MM), and American Brain Tumor Association. Palavalasa was supported by American Cancer Society (PF-23-1077428-01-MM). Venneti was supported by NINDS (R01NS110572 and R01NS127799) and NCI (R01CA261926). Vlashi and Bailleul were supported by NCI (CA251872 and CA251872-S1). Bailleul was supported by a UCLA JCCC Fellowship Award. Park was supported by the National Institute of General Medical Sciences (R35GM143127). Sarkaria was supported by Mayo Clinic and the William H. Donner Professorship.  Agar was supported by the Daniel E. Ponton Fund, National Brain Tumor Society, Mass Life Sciences Center, and NCI(U54CA283114).

    Tech transfer(s)/Conflict(s) of interest: Wahl has consulted for Agios Pharmaceuticals, Admare Pharmaceuticals, Bruker and Innocrin Pharmaceuticals. He is an inventor on patents pertaining to the treatment of patients with brain tumors (U.S. Provisional Patent Application 63/416,146, U.S. Provisional Patent Application 62/744,342, U.S. Provisional Patent Applicant 62/724,337). Scott, Nagrath, Lyssiotis, Mittal, Achreja and Meghdadi are co-inventors on U.S. Provisional Patent Application 63/416,146. In the past three years, Lyssiotis has consulted for Odyssey Therapeutics and Third Rock Ventures. Al-Holou has consulted for Servier Pharmaceuticals. Agar reports the following disclosures: key opinion leader to Bruker Daltonics, collaboration with Thermo Finnigan, service agreement with EMD Serono, service agreement with iTeos Therapeutics, and founder and board member of BondZ.

    Never miss a breakthrough: Join the SciTechDaily newsletter.

    Continue Reading

  • Pakistan to host its first-ever T20I tri-series on home soil

    Pakistan to host its first-ever T20I tri-series on home soil



    Shaheen Shah Afridi dealt an early blow, Afghanistan vs Pakistan, UAE T20I tri-series, Sharjah, August 29, 2025. — AFP

    The Pakistan Cricket Board (PCB) said it will host its first-ever T20 International tri-series later this year, with Pakistan, Afghanistan, and Sri Lanka taking part.

    The tournament is scheduled to start on November 17, when Pakistan face Afghanistan at the Rawalpindi Cricket Stadium, according to a PCB press release.

    The board said the event is designed to give all three sides valuable preparation ahead of the ICC Men’s T20 World Cup, set to be held next year in India and Sri Lanka.

    This will be Afghanistan’s first-ever T20I in Pakistan, having earlier played five ODIs in the country, the last of which was against Australia during the ICC Champions Trophy in February this year.

    As per the schedule, Sri Lanka will face Afghanistan on November 19 at the Rawalpindi Cricket Stadium, while the remaining five T20Is of the tri-series, including the final on November 29, will be played at the Gaddafi Stadium in Lahore.

    Earlier, in October/November, Pakistan will host South Africa for a two-match Test series – part of ICC World Test Championship 2025-27, as well as three T20Is and three ODIs from 12 October to 8 November.

    PCB Chief Operating Officer Sumair Ahmed said: “We look forward to hosting Sri Lanka and Afghanistan for Pakistan’s maiden T20I tri-series. This event will not only offer excellent preparation for next year’s ICC Men’s T20 World Cup but also present fans with exciting cricket across venues.

    “Earlier this year, PCB successfully delivered the ICC Champions Trophy and the ICC Women’s Cricket World Cup Qualifier. These achievements underline our capacity and readiness to host back-to-back international events at the highest level.”

    Tri-series schedule

    17th November — Pakistan v Afghanistan, Rawalpindi Cricket Stadium, Rawalpindi

    19th November — Sri Lanka v Afghanistan, Rawalpindi Cricket Stadium, Rawalpindi

    22th November — Pakistan v Sri Lanka, Gaddafi Stadium, Lahore

    23th November — Pakistan v Afghanistan, Gaddafi Stadium, Lahore

    25th November — Sri Lanka v Afghanistan, Gaddafi Stadium, Lahore

    27th November — Pakistan v Sri Lanka, Gaddafi Stadium, Lahore

    29th November — Final, Gaddafi Stadium, Lahore

    Continue Reading

  • Oncology Updates You Need to Know

    Oncology Updates You Need to Know

    Welcome to this week’s edition of The Targeted Pulse, your weekly wrap-up of the top developments in oncology. This week, we saw several breakthroughs in targeted therapies and FDA decisions, bringing renewed hope to patients and clinicians alike. From regulatory designations for promising new drugs to crucial clinical trials, here are the top stories that shaped the week.

    FDA Grants Orphan Status to Novel JAK2 Inhibitor for Polycythemia Vera

    The FDA has granted orphan drug designation to VGT-1849B, a new investigational drug for the treatment of polycythemia vera (PV). This rare blood cancer, caused by the JAK2 V617F mutation, results in an overproduction of blood cells. VGT-1849B is a novel peptide nucleic acid-based antisense oligonucleotide (ASO) that selectively targets and reduces the production of the JAK2 protein. Unlike current JAK inhibitors, this targeted approach is expected to have a better safety profile and fewer side effects. The orphan drug designation highlights the need for new treatment options for PV patients and provides incentives for the drug’s development.

    Abemaciclib Significantly Improves Overall Survival in High-Risk Early Breast Cancer

    Abemaciclib (Verzenio), in combination with endocrine therapy, has been shown to significantly improve overall survival in patients with high-risk, early breast cancer. This finding comes from a 7-year analysis of the phase 3 monarchE trial, which enrolled over 5600 patients. The 2-year treatment regimen with abemaciclib also provided long-term benefits in disease-free and distant relapse-free survival. The study’s results are considered “practice-changing,” establishing abemaciclib as a new standard of care for this patient population. The safety profile of the treatment remained consistent, with manageable adverse effects. The data validates the drug’s role in reducing the risk of recurrence.

    TT125-802 Gains FDA Fast Track Designation in NSCLC

    A new small-molecule bromodomain inhibitor, TT125-802, has been granted 2 fast track designations by the FDA for the treatment of advanced or metastatic non–small cell lung cancer (NSCLC). This dual designation applies to patients whose disease has progressed after treatment with either an EGFR or a KRAS G12C inhibitor. The fast track status is intended to expedite the drug’s development to address an urgent unmet medical need.

    Initial data from an ongoing phase 1 clinical trial has shown promising results, with durable responses in drug-resistant NSCLC. Notably, the drug’s safety profile is considered favorable, as it does not cause thrombocytopenia, a common adverse effect of similar inhibitors. This allows for higher dosing to maximize the antitumor effect.

    FDA Approves 3-Month Leuprolide Mesylate Formulation for Advanced Prostate Cancer

    The FDA has approved a new 3-month, ready-to-use, long-acting injectable formulation of leuprolide mesylate (Camcevi ETM) for the treatment of advanced prostate cancer. This new quarterly injection, which comes in a prefilled syringe, aims to simplify administration and reduce handling errors.

    The approval was based on a phase 3 clinical trial that demonstrated high efficacy, with 97.9% of patients achieving the primary end point of testosterone suppression to castrate levels. The trial also confirmed that the drug’s safety profile was consistent with other GnRH agonists, with common side effects being mild to moderate in intensity. This new formulation provides a convenient option for managing advanced prostate cancer through androgen deprivation therapy.

    FDA Grants Breakthrough Designation for ctDNA Test in Colorectal Cancer

    The Haystack MRD test, a circulating tumor DNA (ctDNA) assay developed by Quest Diagnostics, has received breakthrough device designation from the FDA. This designation recognizes the test’s potential to significantly improve the management of minimal residual disease (MRD) in patients with stage II colorectal cancer following surgery. The test uses ultrasensitive sequencing to detect microscopic cancer remnants in the bloodstream, often months before they would be visible on a CT scan.

    The designation will accelerate the test’s review and approval, bringing a more precise and timelier tool to clinicians. By identifying patients who may benefit from adjuvant therapy, the test can help guide personalized treatment decisions, reduce unnecessary chemotherapy exposure, and improve patient outcomes.

    Continue Reading

  • WCH Tokyo 25 preview: women’s 5000m | News | Tokyo 25

    WCH Tokyo 25 preview: women’s 5000m | News | Tokyo 25

    • Four fastest women in the history of the 5000m will be in Tokyo
    • Double Olympic champion Beatrice Chebet and defending champion Faith Kipyegon go head-to-head
    • Italy’s Nadia Battocletti and USA’s Josette Andrew have both bettered 14:30 this year

    The four fastest women in history will be in contention in the women’s 5000m at the World Athletics Championships Tokyo 25, though the focus will be on global champions Faith Kipyegon and Beatrice Chebet in what will be their first clash since the Paris 2024 Olympic Games.

    Chebet, the double Olympic champion, became the first woman to cover 5000m within 14 minutes with her world record of 13:58.06 at the Prefontaine Classic in July. The race, which doubled as the Kenyan Trials, also featured Agnes Ngetich and Gudaf Tsegay, who clocked 14:01.29 and 14:04.41 respectively.

    The 2022 silver medallist and a bronze medal winner a year after that, Chebet will be keen to complete her set of World Championship medals when she takes on Kipyegon, her idol and the defending champion.

    Kipyegon, 31, hasn’t raced in the 5000m since the Paris Olympics, where she took silver behind Chebet. Three weeks ago in Silesia, she threatened the long-standing world 3000m record with 8:07.04, the second-fastest time in history, bumping Chebet’s 8:11.56 down to third on the world all-time list.

    Chebet and Kipyegon will have reinforcement from Agnes Ngetich and Japan-based Margaret Akidor. Ngetich, the third-fastest woman in history at 5000m and world record-holder for 10km, has grown in confidence on the track this year with wins in Brussels and Miramar.

    The Kenyan quartet is aiming for a sweep of the medals, but Tsegay may have something to say about that. The Ethiopian, who won the world 5000m title in 2022 and the world 10,000m crown in 2023, will be keen to make amends after coming away from the Paris Olympics without a medal.

    Tsegay is joined on the Ethiopian team by world indoor 3000m champion Freweyni Hailu, who set a PB of 14:19.33 in Rome earlier this year, world U20 record-holder Birke Haylom, and two-time world U20 champion Medina Eisa. It’s not clear yet exactly which three team members will take to the start line.

    The 5000m won’t solely be an East African battle, though.

    Olympic 10,000m silver medallist Nadia Battocletti reduced her own Italian record to 14:23.15 earlier this year. She has also set national records at 3000m (8:26.27) and 5km (14:32).

    Josette Andrews, making her outdoor World Championships debut, is the fastest US entrant after setting a PB of 14:25.37 in Rome. Teammate Shelby Houlihan, winner of the US 5000m title, could also feature.

    Australia’s Rose Davies, Spain’s Marta Garcia, and Britain’s double European U20 champion Innes FitzGerald are also among the athletes to watch.

    Michelle Katami for World Athletics

    Continue Reading